ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
News
DemoDay at La Salle Technova
We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates.
https://twitter.com...
Marta BarrachinaCEO
CO-FOUNDER Ramón ReñéCHIEF MEDICAL OFFICER
CO-FOUNDER
MD, PhD in Medicine and Surgery
(Autonomous University of Barcelona) Jordi GascónCHIEF SCIENTIFIC OFFICER
CO-FOUNDER
MD in Medicine and Surgery
(Autonomous University of Barcelona)
This website uses cookies, both our own and third party cookies, to improve your online experience and collect statistical information on browsing patterns.
By continuing to use this website, you consent cookies being installed on your browser. More information on our Cookies Policy
RigurosityOur clinical studies are rigurously analyzed 
EfficiencyWe optimize our own resources 
AgilityWe adopt agile decissions 
Marta BarrachinaCEO
Ramón ReñéCHIEF MEDICAL OFFICER
Jordi GascónCHIEF SCIENTIFIC OFFICER